Alteration of the platelet transcriptome in chronic kidney disease

Thrombosis and Haemostasis

Volumn 108, Issue 4, 2012, Pages 605-615

  Plé, Hélène ^a,b   Maltais, Manon ^c   Corduan, Aurélie ^a,b   Rousseau, Guy ^c   Madore, François ^c   Provost, Patrick ^a,b  

^a University Laval   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

Chronic kidney disease; Gene expression; MicroRNA; mRNA; Platelets

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; COP9 SIGNALOSOME; FIREFLY LUCIFERASE; LIGASE; LYSOPHOSPHATIDIC ACID RECEPTOR; MESSENGER RNA; METALLOTHIONEIN; MICRORNA; OXYSTEROL; PHOSPHATIDYLCHOLINE; RAB PROTEIN; RENILLA LUCIFERIN 2 MONOOXYGENASE; TRANSCRIPTOME; UNCLASSIFIED DRUG; UREMIC TOXIN; WD REPEAT CONTAINING PROTEIN 1;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIALYSIS; FEMALE; GENE EXPRESSION; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN CELL; MALE; MICROARRAY ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTE DISORDER; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA; UREMIA; VALIDATION PROCESS;

ADULT; AGED; BLOOD PLATELET DISORDERS; BLOOD PLATELETS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MICROFILAMENT PROTEINS; MICRORNAS; MIDDLE AGED; PHOSPHOLIPID TRANSFER PROTEINS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RNA, MESSENGER; TRANSCRIPTOME; UREMIA;

EID: 84867261313     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-03-0153     Document Type: Article

References (48)

1. Collins AJ, Li S, Ma JZ, et al. Cardiovascular disease in end-stage renal disease patients. Am J Kidney Dis 2001; 38 (4 Suppl 1): S26-29.
2. Foley RN, Murray AM, Li S, et al. Chronic Kidney Disease and the Risk for Cardiovascular Disease, Renal Replacement, and Death in the United States Medicare Population, 1998 to 1999. J Am Soc Nephrol 2005; 16: 489-495.
3. Sidhu MS, Dellsperger KC. Cardiovascular problems in dialysis patients: impact on survival. Adv Perit Dial 2010; 26: 47-52.
4. Cheung AK, Sarnak MJ, Yan G, et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000; 58: 353-362.
5. Xue JL, Frazier ET, Herzog CA, et al. Association of heart disease with diabetes and hypertension in patients with ESRD. Am J Kidney Dis 2005; 45: 316-323.
6. Libetta C, Sepe V, Esposito P, et al. Oxidative stress and inflammation: Implications in uremia and hemodialysis. Clin Biochem 2011; 44: 1189-1198.
7. Vaziri ND, Norris K. Lipid disorders and their relevance to outcomes in chronic kidney disease. Blood Purif 2011; 31: 189-196.
8. Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost 2004; 30: 579-589.
9. Rios DR, Carvalho MG, Lwaleed BA, et al. Hemostatic changes in patients with end stage renal disease undergoing hemodialysis. Clin Chim Acta 2010; 411: 135-139.
10. Kaw D, Malhotra D. Platelet dysfunction and end-stage renal disease. Semin Dial 2006; 19: 317-322.
11. Aggarwal A, Kabbani SS, Rimmer JM, et al. Biphasic effects of hemodialysis on platelet reactivity in patients with end-stage renal disease: a potential contributor to cardiovascular risk. Am J Kidney Dis 2002; 40: 315-322.
12. Kabbani SS, Watkins MW, Ashikaga T, et al. Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary inter-vention. Circulation 2001; 104: 181-186.
13. Thaulow E, Erikssen J, Sandvik L, et al. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991; 84: 613-617.
14. Trip MD, Cats VM, van Capelle FJ, et al. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990; 322: 1549-1554.
15. Rowley JW, Oler AJ, Tolley ND, et al. Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes. Blood 2011; 118: e101-111.
16. Roth GJ, Hickey MJ, Chung DW, et al. Circulating human blood platelets retain appreciable amounts of poly (A)+ RNA. Biochem Biophys Res Commun 1989; 160: 705-710.
17. Schubert P, Devine DV. De novo protein synthesis in mature platelets: a consideration for transfusion medicine. Vox Sang 2010; 99: 112-122.
18. Cecchetti L, Tolley ND, Michetti N, et al. Megakaryocytes differentially sort mRNAs for matrix metalloproteinases and their inhibitors into platelets: a mechanism for regulating synthetic events. Blood 2011; 118: 1903-1911.
19. Weyrich AS, Denis MM, Schwertz H, et al. mTOR-dependent synthesis of Bcl-3 controls the retraction of fibrin clots by activated human platelets. Blood 2007; 109: 1975-1983.
20. Evangelista V, Manarini S, Di Santo A, et al. De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. Circ Res 2006; 98: 593-595.
21. Walkowiak B, Kaminska M, Okroj W, et al. The blood platelet proteome is changed in UREMIC patients. Platelets 2007; 18: 386-388.
22. Marques M, Sacristan D, Mateos-Caceres PJ, et al. Different protein expression in normal and dysfunctional platelets from uremic patients. J Nephrol 2010; 23: 90-101.
23. Tassies D, Reverter JC, Cases A, et al. Reticulated platelets in uremic patients: effect of hemodialysis and continuous ambulatory peritoneal dialysis. Am J Hematol 1995; 50: 161-166.
24. Schoorl M, Bartels PCM. Changes in platelet volume, morphology and RNA content in subjects treated with haemodialysis. Scand J Clin Lab Invest 2008; 68:335-342.
25. Landry P, Plante I, Ouellet DL, et al. Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol 2009; 16: 961-966.
26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402-408.
27. Nagalla S, Shaw C, Kong X, et al. Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood 2011; 117: 5189-5197.
28. Griffiths-Jones S. The microRNA Registry. Nucleic Acids Res 2004; 32 (Database issue): D109-111.
29. Xiao F, Zuo Z, Cai G, et al. miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res 2009; 37 (Database issue): D105-110.
30. Plante I, Davidovic L, Ouellet DL, et al. Dicer-derived microRNAs are utilized by the fragile X mental retardation protein for assembly on target RNAs. J Biomed Biotechnol 2006; 2006: 643-647.
31. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
32. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
33. Vanholder R, Cornelis R, Dhondt A, et al. The role of trace elements in uraemic toxicity. Nephrol Dial Transplant 2002; 17 (Suppl 2): 2-8.
34. Tubek S, Grzanka P, Tubek I. Role of Zinc in Hemostasis: A Review. Biological Trace Element Res 2008; 121: 1-8.
35. Foster M, Samman S. Zinc and redox signaling: perturbations associated with cardiovascular disease and diabetes mellitus. Antioxid Redox Signal 2010; 13: 1549-1573.
36. Kadota Y, Suzuki S, Ideta S, et al. Enhanced metallothionein gene expression induced by mitochondrial oxidative stress is reduced in phospholipid hydroperoxide glutathione peroxidase-overexpressed cells. Eur J Pharmacol 2010; 626: 166-170.
37. Fujii H, Nakai K, Fukagawa M. Role of Oxidative Stress and Indoxyl Sulfate in Progression of Cardiovascular Disease in Chronic Kidney Disease. Therap Apheresis Dialysis 2011; 15: 125-128.
38. Pamuklar Z, Lee JS, Cheng H-Y, et al. Individual Heterogeneity in Platelet Response to Lysophosphatidic Acid. Arterioscl Thromb Vasc Biol 2008; 28: 555-561.
39. Cui MZ. Lysophosphatidic acid effects on atherosclerosis and thrombosis. Clin Lipidol 2011; 6: 413-426.
40. Di Minno G, Martinez J, McKean M-L, et al. Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. Am J Med 1985; 79: 552-559.
41. Vecino AM, Teruel JL, Navarro JL, et al. Phospholipase A2 activity in platelets of patients with uremia. Platelets 2002; 13: 415-418.
42. Bonomini M, Dottori S, Amoroso L, et al. Increased platelet phosphatidylserine exposure and caspase activation in chronic uremia. J Thromb Haemost 2004; 2:1275-1281.
43. Vecino A, Navarro-Antolin J, Teruel J, et al. Lipid composition of platelets in patients with uremia. Nephron 1998; 78: 271-273.
44. Saj A, Lai EC. Control of microRNA biogenesis and transcription by cell signaling pathways. Curr Opin Genet Develop 2011; 21: 504-510.
45. Huntzinger E, Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet 2011; 12: 99-110.
46. Guo H, Ingolia NT, Weissman JS, et al. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010; 466: 835-840.
47. Kondkar AA, Bray MS, Leal SM, et al. VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA. J Thromb Haemost 2010; 8: 369-378.
48. Sondermeijer BM, Bakker A, Halliani A, et al. Platelets in Patients with Premature Coronary Artery Disease Exhibit Upregulation of miRNA340* and miRNA624*. PLoS One 2011; 6: e25946.